Blood-brain barrier efflux transport

被引:102
作者
Golden, PL
Pollack, GM [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA
[2] Bristol Myers Squibb Co, Drug Metab & Pharmacokinet, Wilmington, DE 19880 USA
关键词
blood-brain barrier; efflux transport; P-glycoprotein; brain uptake; microdialysis;
D O I
10.1002/jps.10424
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Efflux transport at the blood-brain barrier (BBB) limits the brain tissue exposure to a variety of potential therapeutic agents, including compounds that are relatively lipophilic and would be predicted to permeate the endothelial lining of the brain microvasculature. Recent advances in molecular and cell biology have led to identification of several specific transport systems at the blood-brain interface. Refinement of classical pharmacokinetic experimentation has allowed assessment of the structural specificity of transporters, the impact of efflux transport on brain tissue exposure, and the potential for drug-drug interactions at the level of BBB efflux transport. The objective of this minireview is to summarize efflux transporter characteristics (location, specificity, and potential inhibition) for transport systems identified in the BBB. A variety of experimental approaches available to ascertain or predict the impact of efflux transport on net brain tissue uptake of substrates also are presented. The potential impact of efflux transport on the pharmacodynamics of agents acting in the central nervous system are illustrated. Finally, general issues regarding the role of identifying efflux transport as part of the drug development process are discussed. (C) 2003 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:1739 / 1753
页数:15
相关论文
共 130 条
[21]   BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123 [J].
de Lange, ECM ;
de Bock, G ;
Schinkel, AH ;
de Boer, AG ;
Breimer, DD .
PHARMACEUTICAL RESEARCH, 1998, 15 (11) :1657-1665
[22]  
Declèves X, 2000, J NEUROSCI RES, V60, P594, DOI 10.1002/(SICI)1097-4547(20000601)60:5<594::AID-JNR4>3.0.CO
[23]  
2-6
[24]  
Deguchi Y, 1997, J PHARMACOL EXP THER, V280, P551
[25]   Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier [J].
deLange, ECM ;
Danhof, M ;
deBoer, AG ;
Breimer, DD .
BRAIN RESEARCH REVIEWS, 1997, 25 (01) :27-49
[26]   Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine [J].
Desrayaud, S ;
Guntz, P ;
Scherrmann, JM ;
Lemaire, M .
LIFE SCIENCES, 1997, 61 (02) :153-163
[27]   DECREASED BIOTOLERABILITY FOR IVERMECTIN AND CYCLOSPORINE-A IN MICE EXPOSED TO POTENT P-GLYCOPROTEIN INHIBITORS [J].
DIDIER, AD ;
LOOR, F .
INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (02) :263-267
[28]  
Doze P, 2000, SYNAPSE, V36, P66, DOI 10.1002/(SICI)1098-2396(200004)36:1<66::AID-SYN7>3.0.CO
[29]  
2-J
[30]  
Drion N, 1997, J NEUROSCI RES, V49, P80